Key result
Hydrogen sulfide-releasing compounds show preclinical potential for CVD by inhibiting atherosclerosis and cardiac remodeling.
Why the study?
Do hydrogen sulfide (H2S)-releasing compounds have therapeutic potential in cardiovascular diseases?
Do hydrogen sulfide (H2S)-releasing compounds have therapeutic potential in cardiovascular diseases?
H2S-releasing compounds represent a potential therapeutic strategy for various cardiovascular diseases due to their protective mechanistic actions.
Supports H2S compound development for CVD; leaves open clinical translation from preclinical models.
Cardiovascular disease is the main cause of death worldwide, but its pathogenesis is not yet clear. Hydrogen sulphide (H2S) is considered to be the third most important endogenous gasotransmitter in the organism after carbon monoxide (CO) and nitric oxide (NO). It can be synthesized in mammalian tissues and can freely cross the cell membrane and exert many biological effects in various systems including cardiovascular system. More and more recent studies have supported the protective effects of endogenous H2S and exogenous H2S-releasing compounds (such as NaHS, Na2S, GYY4137 etc) in cardiovascular diseases, such as cardiac hypertrophy, heart failure, ischemia/reperfusion injury, and atherosclerosis. Here, we provided an up-to-date overview of the mechanistic actions of H2S as well as the therapeutic potential of various classes of H2S donors in treating cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2018) conducted a review in Cardiovascular Diseases. Hydrogen Sulfide (H2S)-Releasing Compounds was evaluated. Hydrogen sulfide-releasing compounds demonstrate therapeutic potential in cardiovascular diseases by inhibiting atherosclerosis, cardiac remodeling, and ischemia-reperfusion injury in preclinical models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: